Edition:
United States

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

141.83USD
23 Jan 2018
Change (% chg)

$-6.31 (-4.26%)
Prev Close
$148.14
Open
$147.02
Day's High
$147.44
Day's Low
$141.63
Volume
4,042,285
Avg. Vol
1,986,865
52-wk High
$148.32
52-wk Low
$110.76

Latest Key Developments (Source: Significant Developments)

Novartis says data reinforces ‍Cosentyx effectiveness
Tuesday, 16 Jan 2018 01:15am EST 

Jan 16 (Reuters) - Novartis AG ::NOVARTIS NEW DATA REINFORCES SUPERIORITY OF COSENTYX® VERSUS STELARA®* IN ACHIEVING SKIN CLEARANCE FOR PSORIASIS PATIENTS.‍CLARITY STUDY SHOW COSENTYX(®) (SECUKINUMAB) WAS SIGNIFICANTLY MORE EFFECTIVE THAN STELARA(®*) (USTEKINUMAB) IN DELIVERING CLEAR AND ALMOST CLEAR SKIN AT 12 WEEKS AND AT 16 WEEKS​.‍COSENTYX CONTINUED TO HAVE A FAVORABLE AND CONSISTENT SAFETY PROFILE​.  Full Article

Halozyme Projects 25 To 30 Percent Enhanze Royalty Growth In 2018
Tuesday, 9 Jan 2018 06:30pm EST 

Jan 9 (Reuters) - Halozyme Therapeutics Inc ::HALOZYME PROJECTS 25 TO 30 PERCENT ENHANZE ROYALTY GROWTH IN 2018.HALOZYME THERAPEUTICS INC - ‍ FORECASTS POTENTIAL ROYALTY REVENUE FOR ENHANZE TO REACH NEARLY $1 BILLION IN 2027 ​.HALOZYME THERAPEUTICS INC - ‍EXPECTS ADDITIONAL PARTNERS TO BEGIN THREE PHASE 1 STUDIES WITH NEW TARGETS FOR ENHANZE​ IN 2018.  Full Article

Geron-Latest Time For Janssen Continuation Decision To Continue Development Of Imetelstat In Any Indication Expected By Q4 2018/Q1 2019
Monday, 8 Jan 2018 07:57am EST 

Jan 8 (Reuters) - Geron Corp ::GERON -LATEST TIME FOR JANSSEN CONTINUATION DECISION TO CONTINUE DEVELOPMENT OF IMETELSTAT IN ANY INDICATION EXPECTED BY Q4 2018/Q1 2019 - SEC FILING‍​.  Full Article

Landmark Schizophrenia Data Receive FDA Approval For Inclusion In Invega Sustenna (Paliperidone Palmitate) Label
Wednesday, 3 Jan 2018 08:00am EST 

Jan 3 (Reuters) - Johnson & Johnson ::LANDMARK SCHIZOPHRENIA DATA THAT BRING HOPE IN BREAKING THE CYCLE OF HOSPITALIZATION AND INCARCERATION RECEIVE FDA APPROVAL FOR INCLUSION IN INVEGA SUSTENNA® (PALIPERIDONE PALMITATE) LABEL.JANSSEN PHARMACEUTICALS SAYS INVEGA SUSTENNA IS THE FIRST ANTIPSYCHOTIC TO HAVE U.S. FDA APPROVE INCLUSION OF REAL-WORLD DATA IN ITS PRODUCT LABELING.  Full Article

Syros Announces Clinical Supply Agreement With Janssen To Evaluate SY-1425
Tuesday, 2 Jan 2018 08:01am EST 

Jan 2 (Reuters) - Syros Pharmaceuticals Inc ::SYROS ANNOUNCES CLINICAL SUPPLY AGREEMENT WITH JANSSEN TO EVALUATE SY-1425, ITS FIRST-IN-CLASS SELECTIVE RARΑ AGONIST, IN COMBINATION WITH DARATUMUMAB IN GENOMICALLY DEFINED AML AND MDS PATIENTS.SYROS PHARMACEUTICALS - JANSSEN TO SUPPLY DARATUMUMAB FOR COMBINATION DOSING COHORT IN SYROS' ONGOING PHASE 2 CLINICAL TRIAL OF SY-1425.SYROS PHARMACEUTICALS - JANSSEN TO RECEIVE ACCESS TO DATA FROM COHORT EVALUATING SAFETY & EFFICACY OF SY-1425 IN COMBINATION WITH DARATUMUMAB FOR RESEARCH AND DEVELOPMENT.SYROS PHARMACEUTICALS - ‍EXPECTS TO BEGIN ENROLLING PATIENTS IN COMBINATION COHORT WITH DARATUMUMAB IN EARLY 2018​.  Full Article

Genscript Biotech Says US, Ireland Units ‍& Janssen Biotech Enter Collaboration & License Agreement ​
Thursday, 21 Dec 2017 05:05pm EST 

Dec 22 (Reuters) - Genscript Biotech Corp <1548.HK>::US, IRELAND UNITS ‍& JANSSEN BIOTECH ENTER COLLABORATION & LICENSE AGREEMENT TO DEVELOP MULTIPLE MYELOMA PRODUCTS ​.‍ACCORDING TO DEAL , JANSSEN SHALL UPFRONT PAYMENTS OF US$350 MILLION TO UNIT FOR RIGHTS GRANTED​.  Full Article

Janssen Enters Collaboration And License Agreement With China's Legend Biotech To Develop CAR-T Cancer Therapy
Thursday, 21 Dec 2017 05:00pm EST 

Dec 21 (Reuters) - Johnson & Johnson ::JANSSEN ENTERS WORLDWIDE COLLABORATION AND LICENSE AGREEMENT WITH CHINESE COMPANY LEGEND BIOTECH TO DEVELOP INVESTIGATIONAL CAR-T ANTI-CANCER THERAPY.JANSSEN BIOTECH - J&J REAFFIRMS FY 2017 ADJUSTED EARNINGS PER SHARE GUIDANCE OF $7.25 - $7.30.FY2017 EARNINGS PER SHARE VIEW $7.28 -- THOMSON REUTERS I/B/E/S.JANSSEN - ENTERED INTO WORLDWIDE COLLABORATION, LICENSE DEAL WITH UNITS OF GENSCRIPT BIOTECH CORPORATION.JANSSEN SAYS UNDER AGREEMENT, IT WILL MAKE AN UPFRONT PAYMENT OF $350 MILLION THAT WILL BE RECORDED IN Q4.JANSSEN SAYS COS ENTERED INTO A 50/50% COST-SHARING/PROFIT-SPLIT ARRANGEMENT, EXCEPT IN GREATER CHINA.JANSSEN SAYS IN GREATER CHINA, JANSSEN AND LEGEND HAVE A 30/70 PERCENT COST-SHARING/PROFIT-SPLIT ARRANGEMENT.  Full Article

Janssen Submits Supplemental NDA To FDA Seeking New Indications For Xarelto
Monday, 11 Dec 2017 08:30am EST 

Dec 11 (Reuters) - Johnson & Johnson ::JANSSEN SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO FDA SEEKING NEW INDICATIONS FOR XARELTO® (RIVAROXABAN) FOR PATIENTS WITH CHRONIC CORONARY AND/OR PERIPHERAL ARTERY DISEASE (CAD/PAD).JANSSEN SUBMITS SUPPLEMENTAL NDA TO FDA SEEKING NEW INDICATIONS FOR XARELTO FOR PATIENTS WITH CHRONIC CORONARY AND/OR PERIPHERAL ARTERY DISEASE.  Full Article

J&J considers sale of anti-dandruff shampoo Nizoral - Bloomberg
Thursday, 7 Dec 2017 12:00pm EST 

Dec 7 (Reuters) - :J&J CONSIDERS SALE OF ANTI-DANDRUFF SHAMPOO NIZORAL- BLOOMBERG,CITING SOURCES‍​.SALE OF J&J'S NIZORAL COULD BE VALUED AT A FEW HUNDRED MILLION DOLLARS- BLOOMBERG,CITING SOURCES‍​.  Full Article

Genomic Health Announces Research Collaboration with Janssen Pharma
Wednesday, 6 Dec 2017 08:00am EST 

Dec 6 (Reuters) - Genomic Health Inc ::GENOMIC HEALTH ANNOUNCES RESEARCH COLLABORATION WITH JANSSEN PHARMACEUTICALS TO EVALUATE THE ONCOTYPE DX® GENOMIC PROSTATE SCORE™ TEST FOR POTENTIAL DRUG DEVELOPMENT.GENOMIC HEALTH - AS PER AGREEMENT, CO WILL TEST SAMPLES FROM JANSSEN STUDIES TO EXAMINE ASSOCIATION OF GENOMIC PROSTATE SCORE RESULTS WITH CLINICAL OUTCOMES.  Full Article

J&J mesothelioma talc trial postponed as N.J. judge reverses expert ruling

A New Jersey state court judge on Monday delayed the start of a trial by a man who said he developed mesothelioma from being exposed to Johnson & Johnson's talc products after reversing a previous ruling that had barred a defense expert from testifying.